8-K: FutureTech II Acquisition Corp. Settles Underwriting Commission with D. Boral Capital Ahead of Longevity Biomedical Merger

FutureTech II Acquisition Corp. reaches an agreement with D. Boral Capital to settle a deferred underwriting commission related to its IPO by using a combination of cash, a promissory note, and company stock, contingent on the closing of its business combination with Longevity Biomedical Inc.

Summary

• FutureTech II Acquisition Corp. and Longevity Biomedical Inc. have agreed with D. Boral Capital LLC to settle a deferred underwriting commission of $3,450,000 related to FutureTech's IPO.
• Instead of receiving the full amount in cash upon the closing of the business combination with Longevity, D. Boral will receive $500,000 in cash.
• D. Boral will also receive a $1,475,000 promissory note from FutureTech and Longevity, payable by the maturity date.
• Additionally, D. Boral will receive 147,500 shares of FutureTech's common stock, valued at $10.00 per share, totaling $1,475,000.
• The agreement is contingent upon the successful completion of the business combination between FutureTech and Longevity.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The agreement settles an obligation but also introduces a promissory note and equity dilution.

Positives

• FutureTech is able to reduce its immediate cash outlay for the underwriting commission by using a combination of cash, a promissory note, and company stock.
• The agreement provides certainty regarding the underwriting commission ahead of the business combination with Longevity Biomedical Inc.

Negatives

• FutureTech is incurring a financial obligation in the form of a $1,475,000 promissory note.
• FutureTech is diluting existing shareholders by issuing 147,500 shares of common stock to D. Boral Capital.

Risks

• The business combination with Longevity Biomedical Inc. must be completed for the agreement with D. Boral Capital to take effect.
• FutureTech will need to have sufficient cash to repay the $1,475,000 promissory note by the maturity date.

Future Outlook

The document contains forward-looking statements regarding the proposed business combination with Longevity Biomedical Inc., including anticipated enterprise and equity values, benefits of the transaction, and expected timing. These statements are subject to risks and uncertainties.

Industry Context

SPACs (Special Purpose Acquisition Companies) often use deferred underwriting commissions to align the interests of underwriters with the successful completion of a business combination. This settlement reflects a negotiation between FutureTech and its underwriter to manage cash flow and equity dilution.

Comparison to Industry Standards

• SPAC underwriting fees typically range from 2% to 6% of the gross proceeds raised in the IPO.
• Deferred underwriting commissions are a common feature in SPAC deals, often paid upon completion of the business combination.
• Settlements involving a combination of cash, notes, and equity are not uncommon when SPACs seek to conserve cash or negotiate more favorable terms with underwriters.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• D. Boral Capital LLC benefits from the settlement of the deferred underwriting commission.
• FutureTech and Longevity are obligated to repay the promissory note.

Next Steps

• Closing of the business combination between FutureTech II Acquisition Corp. and Longevity Biomedical Inc.
• Issuance of cash, promissory note, and common stock to D. Boral Capital LLC upon closing.
• Repayment of the promissory note by FutureTech and Longevity by the maturity date.

Key Dates

Keywords

FutureTech II Acquisition Corp., Longevity Biomedical Inc., D. Boral Capital, deferred underwriting commission, business combination, promissory note, common stock, IPO, FTII, FTIIU, FTIIW